Department of Electrical and Computer Engineering, Purdue University, West Lafayette, Indiana, USA.
Bionode LLC, Indianapolis, Indiana, USA.
Curr Eye Res. 2021 Oct;46(10):1531-1538. doi: 10.1080/02713683.2021.1904999. Epub 2021 Apr 7.
: To investigate the safety and efficacy of the IOPTx™ system - a novel wearable, electroceutical treatment to lower intraocular pressure. : Patients wear the customized contact lens and spectacles of the IOPTx™ system and undergo three 15-minute randomized stimulation trials at different stimulus amplitudes with 15 minutes of rest in between. The parameters for the stimulation trials include a frequency of 50 Hz, a pulse width of 100 µs, and current amplitudes between 90-150 µA. The optometrist measures the intraocular pressure (IOP) before, immediately after, and 15 minutes after the trial, and performs topography, a slit eye examination, and specular microscopy before and after the entire study to check the health of the eye and confirm the safety of the system. : The IOPTx™ system successfully modulates a patient's IOP. By testing various currents, we create individual tuning curves examining the effect of the stimulation amplitude on the change in IOP. Each patient may have an optimal dose-response curve and by normalizing to this value, the IOPTx™ system decreased IOP by an average of 17.7% with fifteen minutes of therapy. No Adverse Events or Adverse Device Effects occurred.: The results of this clinical case series provide preliminary evidence of efficacy and safety of the IOPTx™ system and its potential usefulness to lower IOP in glaucoma and ocular hypertension.
: 研究目的是评估 IOPTx™ 系统——一种新型可穿戴、电疗设备降低眼内压的安全性和有效性。 : 患者佩戴 IOPTx™ 系统定制的隐形眼镜和眼镜,并在不同刺激幅度下进行三次 15 分钟的随机刺激试验,每次试验之间休息 15 分钟。刺激试验的参数包括频率为 50Hz、脉冲宽度为 100µs、电流幅度为 90-150µA。眼科医生在试验前、试验后即刻和试验后 15 分钟测量眼内压(IOP),并在整个研究前后进行地形学、裂隙灯检查和共焦显微镜检查,以检查眼睛的健康状况并确认系统的安全性。 : IOPTx™ 系统成功调节了患者的 IOP。通过测试各种电流,我们创建了个体调谐曲线,研究刺激幅度对 IOP 变化的影响。每位患者可能都有最佳的剂量反应曲线,通过将其标准化,IOPTx™ 系统在 15 分钟的治疗后平均降低了 17.7%的 IOP。没有出现不良事件或不良设备影响。 : 这项临床病例系列研究的结果初步证明了 IOPTx™ 系统的有效性和安全性,以及其在降低青光眼和高眼压症患者眼内压方面的潜在用途。